ArticleClinical and experimental medicine2026
Integrating multi-source data and machine learning to Decipher the psoriasis-COPD comorbidity.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The epidemiological and molecular associations between psoriasis and chronic obstructive pulmonary disease (COPD) remain incompletely elucidated. To explore this association and shared mechanisms, this study integrated data of the National Health and Nutrition Examination Survey (NHANES) 2003–2014 (n = 17,416), assessing this association via multivariable logistic regression and subgroup analysis. Transcriptomic data of psoriasis (skin tissue) and COPD (alveolar macrophages) were retrieved from the Gene Expression Omnibus (GEO) database. Candidate biomarkers were identified via differentially expressed gene (DEG) analysis, weighted gene coexpression network analysis (WGCNA), and machine learning [Random Forest (RF) and least absolute shrinkage and selection operator (LASSO)], followed by validation of their diagnostic efficacy. In the fully weighted and adjusted model, no statistically significant association was found between psoriasis and COPD (OR = 1.25, 95% CI: 0.93–1.68, p = 0.14), although trend-level associations were observed among smokers, individuals with hypertension, and those with unstable marital status. We identified 85 shared differentially expressed genes (DEGs), enriched in inflammatory pathways such as the chemokine signaling pathway, and screened three candidate genes (UCK2, P4HA1, and HIBADH). A RF diagnostic model based on these genes achieved Area Under the Curves (AUCs) of 0.935 for psoriasis and 0.962 for COPD in external validation sets. These findings suggest that the comorbidity between psoriasis and COPD may be influenced by risk factors such as smoking and hypertension, as well as shared inflammatory pathways and differentially expressed genes (DEGs) regulation. Psoriasis could serve as a potential window for early COPD screening and provide novel cross-disease therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.